Skip to main content
  • Contact Us
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
      • CDMO Intelligence
      • Real World Data
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Verastem

Evaluate

Thumbnail
June 09, 2023

Asco 2023 story roundup

Thumbnail
June 08, 2023

Asco 2023 movers – maintaining the momentum

Several biotech stocks maintained throughout Asco the momentum they had going into the meeting, and intrigue over Tigit continued.

Article image
Vantage logo
May 30, 2023

Asco 2023 preview – a microcap winner

One of the most momentous Asco abstracts drops of recent years sends Verastem up 126%.

Article image
Vantage logo
October 12, 2022

Kinnate is the latest Raf player to trip up

The company’s attempt to segment Braf-mutant cancers further isn’t going smoothly.

Article image
Vantage logo
October 03, 2022

US FDA approval tracker: September 2022

Article image
Vantage logo
August 31, 2022

Go or no go? Bristol’s Tyk2 test

A green light from the FDA is expected for deucravacitinib, while Amylyx, Ferring and Oncopeptides head for panels.

Article image
Vantage logo
April 22, 2022

What next for developers seeking to emulate Zydelig?

Article image
Vantage logo
March 31, 2022

Significant readouts for small players

Praxis and Relmada target depression as Athira and Taurx tackle Alzheimer’s.

Article image
Vantage logo
September 24, 2021

Esmo 2021 movers – a handful of biotech winners emerge

Leap and Innate were clear winners on the stock market during the medical meeting, while Astrazeneca’s strong performance stands out among the large caps.

Article image
Vantage logo
July 27, 2021

The markets refuse to forgive Infinity

The company’s second foray with a PI3K inhibitor shows signs of additive activity, but investors punish it all the same.

Article image
Vantage logo
April 28, 2020

AACR 2020 – Not so fast, Trovagene

  • Load More

Latest Reports

July 27, 2023

H1 Round Up: The haves and the have-nots

July 21, 2023

ADA/EASL eBook

View more...

Editor's Picks

Vantage logo
July 03, 2023

Astrazeneca and Daiichi’s big reveal disappoints

Vantage logo
July 13, 2023

Pharma finds a way to gain weight

Vantage logo
July 03, 2023

Protagonist investors flake as psoriasis pill disappoints

Vantage logo
June 29, 2023

Approaching datasets for big pharma

Vantage logo
June 27, 2023

Nkarta goes back to basics

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up